1117-23-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-1,5-pentanediol is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a valuable building block for the development of new drugs with potential therapeutic applications.
Used in the Synthesis of Pamapimod:
3-Amino-1,5-pentanediol is used as a substituent in the synthesis of Pamapimod (P167500), a selective inhibitor of the α-isoform of p38 MAP kinase. 3-AMino-1,5-pentanediol has potential applications in the treatment of various inflammatory and autoimmune diseases, as well as in the development of new therapeutic strategies for cancer treatment.

Upstream product

• 51865-85-1 1,3-diethyl 2-aminoglutarate 
• 2049-67-4 diethyl glutaconate 
• 82803-55-2 3-tert-butoxycarbonylaminopentanedioic acid dimethyl ester 
• 63547-62-6 dimethyl 3-aminoglutaconate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 1092775-83-1 tert-butyl N-[3-hydroxy-1-(2-hydroxyethyl)propyl]carbamate 
• 1034082-96-6 2-(N-benzylamino)pentane-1,5-diol 
• 77313-09-8 3-aminoglutaric acid dimethyl ester 

Downstream Products

• 1092457-58-3 C₁₉H₂₀F₃IN₄O₄ 
• 449811-01-2 [14C]-Pamapimod 

Relevant academic research and scientific papers

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

BICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR

The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl) propylamino]-8-methyl-8 H -pyrido[2,3- d ]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2 H -pyran-4-ylamino)pyrido[2,3- d ]pyrimidin-7(8 H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase

The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38α, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.

Scalable non-aqueous process to prepare water soluble 3-amino-pentan-1,5- diol

The development of a nonaqueous process for the synthesis of 3-amino-pentan-1,5-diol is described. Beginning with dimethyl acetone-1,3-dicarboxylate, a telescoped sequence of reductive amination, Boc protection, sodium borohydride reduction, and acidic resin-mediated deprotection generates the title compound. The key to this efficient process is the telescoped deprotection, purification and nonaqueous isolation of the 3-amino-pentan-1,5- diol. The process involves four optimized chemical reactions using two solvents in 89% overall yield and 97-98 area % purity.

NOVEL PROCESS FOR THE PREPARATION OF 3-AMINO-PENTAN-1,5-DIOL

The present invention provides a novel method for preparing a key intermediate, 3-amino-pentan-1,5-diol (2), which is useful for the preparation of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)-propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidine-7-one (1) a MAP-kinase inhibitor useful in the treatment of rheumatoid arthritis.

JNK modulators

Compounds of formula I modulate JNK: wherein the variables are as defined herein.

Compounds and methods for amino-alkylenediol synthesis

A method of making an amino-alkylenediol and intermediate compounds useful in the method is disclosed. The method includes preparing a first intermediate compound comprising an aminoalkylene diol wherein a protecting group is linked to the amino functionality, and optionally, preparing a second intermediate compound comprising a salt of the first intermediate compound. The first intermediate compound has the structure wherein R is a divalent alkylene radical having from 2 to 20 carbon atoms, X and Y are independently a divalent linking moiety or a single bond, and Z is a protecting group. The second intermediate compound has the structure wherein R is a divalent alkylene radical having from 2 to 20 carbon atoms, X and Y are independently a divalent linking moiety or a single bond, TsO? is toluene sulfonate, and Z is a protecting group.